<DOC>
	<DOCNO>NCT00951457</DOCNO>
	<brief_summary>The primary objective study determine percentage patient achieve response , define percentage patient achieve complete response , partial response stable disease/ change upon treatment combination therapy accord NCI response criterion ( also establish accord IWCLL guideline ) upon treatment combination bendamustine alemtuzumab .</brief_summary>
	<brief_title>Bendamustine Combined With Alemtuzumab Pretreated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>This non-randomized , multicenter , open-label , single-arm Phase I/II study evaluate safety efficacy bendamustine combine alemtuzumab patient pretreated CD20-positive CLL ( accord revise NCI/ IWCLL criterion ) . Eligible patient receive bendamustine 4 course 70 mg/m2 day 1 2 every 28 day 30 mg alemtuzumab s.c. continuously day 1 , 3 5 every week , maximum 16 week . Safety assessment conducted weekly ; efficacy assessment include image performed month 2 , 4 , 6 , 10 16 . Bone marrow biopsy perform upon CR ( accord 2008 IWCLL response criterion ) fix 6 16 month . Following recruitment first 3 7 patient safety evaluation perform data safety monitor board . An interim analysis response safety well maximum tolerate dose level occur first 7 patient complete treatment ( Gehan timepoint ) . If treatment deem clinically safe 13 patient enrol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Male female patient CD23+ , CD5+ , CD19+ light chain monoclonal BCLL treatment indication accord IWCLL criterion ( Appendix 4 ) 1st great relapse fludarabine primary treatment regimen OR Refractory previous treatment simultaneous indication treatment accord IWCLL criterion ( Appendix 4 ) Age 18 year old ECOG status 0 2 Life expectancy &gt; 6 month Written inform consent give patient Patient use reliable mean contraception ( e.g . physical barrier , contraceptive pill patch , spermicide barrier , IUD ) duration study . Male patient use adequate contraception method duration study treatment 6 month follow completion study treatment . Women childbearing potential use effective method contraception duration study participation . HIV positive positive Hepatitis B C Active uncontrolled infection Pregnant lactate woman Hypersensitivity anaphylactic reaction humanise monoclonal antibody excipients apply drug ( e.g . Bendamustine hydrochloride mannitol ) Previous treatment bendamustine Treatment experimental drug within previous 2 month Patients history malignancy within 2 year prior study entry , except adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage localize prostate cancer treat surgically curative intent ; good prognosis DCIS breast treat lumpectomy alone curative intent . Transformation aggressive Bcell malignancy ( e.g . large Bcell lymphoma , Richter 's syndrome , prolymphocytic leukemia ( PLL ) Decreased kidney function creatinine clearance &lt; 30 ml/min Patients severe comorbidities major organ dysfunction ( e.g . know severe liver damage , jaundice ) Patients history severe cardiac disease ; e.g . NYHA Functional Class III IV heart failure , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina Any coexist medical psychological condition would preclude participation study compromise ability give inform consent , patient unable comply requirement study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>CLL</keyword>
	<keyword>pretreated</keyword>
	<keyword>immune therapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Alemtuzumab</keyword>
</DOC>